Echo Therapeutics (Echo Therapeutics) Change In Working Capital : $0.80 Mil (TTM As of Sep. 2016)

View and export this data going back to 1997. Start your Free Trial

What is Echo Therapeutics Change In Working Capital?

Echo Therapeutics's change in working capital for the quarter that ended in Sep. 2016 was $0.92 Mil.

Echo Therapeutics's change in working capital for the fiscal year that ended in Dec. 2015 was $0.82 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Echo Therapeutics Change In Working Capital Historical Data

The historical data trend for Echo Therapeutics's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Echo Therapeutics Change In Working Capital Chart

Echo Therapeutics Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Change In Working Capital

Get a 7-Day Free Trial

-0.01

2.76

-1.46

-0.18

0.82

Echo Therapeutics Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Change In Working Capital	Get a 7-Day Free Trial															0.19	0.52	-0.52	-0.12	0.92

Echo Therapeutics Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.80 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Echo Therapeutics Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Echo Therapeutics's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Echo Therapeutics (Echo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Echo Therapeutics Inc (OTCPK:ECTE) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

99 Wood Avenue South, Suite 302, Iselin, NJ, USA, 08830

Website

http://www.echotx.com

Echo Therapeutics Inc is a medical device company with expertise in skin permeation technology. It develops non-invasive, wireless continuous glucose monitoring system with potential use in the wearable health consumer and the diabetes outpatient market.

Executives

Michael M Goldberg	director	C/O MONTAUR CAPITAL PARTNERS, 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Uri Landesman	10 percent owner	230 PARK AVENUE, NEW YORK NY 10169
Platinum Partners Value Arbitrage Fund, Lp	10 percent owner	250 WEST 55TH STREET, 14TH FLOOR, NEW YORK NY 10019
Mark Nordlicht	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Platinum Management (ny) Llc	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Platinum-montaur Life Sciences, Llc	10 percent owner	152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Partners Liquid Opportunity Master Fund L.p.	10 percent owner	152 WEST 57 STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Liquid Opportunity Management (ny) Llc	10 percent owner	152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Bernhardt Charles Thomas Iii	officer: Interim CFO	23 BIRCH ROAD, MALVERN PA 19355
Vincent D Enright	director	ONE CORPORATE CENTER, RYE NY 10580
William Grieco	director	830 CRESCENT CENTRE DRIVE, SUITE 610, FRANKLIN TN 37067
Platinum Long Term Growth Vii, Llc	10 percent owner	152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Robert F Doman	director, officer: EXEC. CHAIRMAN AND INTERIM CEO	C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE, WILMINGTON MA 01887
Patrick T Mooney	director, officer: CEO AND PRESIDENT	C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Christopher P. Schnittker	officer: CFO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540

Echo Therapeutics (Echo Therapeutics) Headlines

No Headlines